Pricing Log in Create free account

CNS Pharmaceuticals, Inc. (CNSP) vs Orgenesis Inc. (ORGS)

CNS Pharmaceuticals, Inc. and Orgenesis Inc. are both Biotechnology companies. CNS Pharmaceuticals, Inc. and Orgenesis Inc. are of similar size ($5.9M and $5.7M). CNS Pharmaceuticals, Inc. has the higher net margin (0.00% vs −4,653.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, CNS Pharmaceuticals, Inc. leads on 9 and Orgenesis Inc. on 3.

Valuation

Metric CNSP ORGS Biotechnology median
P/E n/m n/m 10.60
P/S n/m 1.42 9.40
P/B 1.46 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales n/m 16.89 9.02
Earnings yield (606.43%) (3,288.57%) (32.88%)
Free cash flow yield (50.55%) (1,176.50%) (23.13%)

Profitability

Metric CNSP ORGS Biotechnology median
Gross margin 0.00% (86.28%) 68.51%
Operating margin 0.00% (3,842.32%) 0.00%
Net margin 0.00% (4,653.62%) 0.00%
Free cash flow margin 0.00% (1,675.27%) 0.00%
Return on equity (106.62%) 164.62% (51.96%)
Return on assets (91.64%) (605.73%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CNSP ORGS Biotechnology median
Revenue growth (TTM) — 95.28% 6.76%
EPS growth (last fiscal year) 92.34% 40.10% 29.88%
Revenue growth, 5-year CAGR — (23.30%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CNSP ORGS Biotechnology median
Debt to equity 0.00 (0.44) 0.00
Current ratio 5.86 0.03 4.97
Net debt to EBITDA 0.45 (0.42) 1.01

Dividend

Metric CNSP ORGS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CNSP ORGS Biotechnology median
Market cap 5.86m 5.68m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack